<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007395.ref021">
 <label>21</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Gaudet</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Méthot</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Déry</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Brisson</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Essiembre</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>Tremblay</surname>
   <given-names>G</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial</article-title>. 
  <source>Gene Ther. Macmillan Publishers Limited</source>; 
  <year>2013</year>;
  <volume>20</volume>: 
  <fpage>361</fpage>–
  <lpage>9</lpage>. 
  <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/gt.2012.43" xmlns:xlink="http://www.w3.org/1999/xlink">10.1038/gt.2012.43</ext-link>
  <?supplied-pmid 22717743?>
  <pub-id pub-id-type="pmid">22717743</pub-id>
 </mixed-citation>
</ref>
